Nov 01st 2012 - Edison Investment Research today published a report on Clinigen (CLIN.L, LSE:CLIN, LON:CLIN) entitled "Leave Leaver Out". In summary, the report says:
Clinigen’s IPO generated almost as much comment for the terms of founder Andrew Leaver’s exit from the company as for the investment case. Yet it is a fast-growing business (revenues up 97% and EBITDA up 215% in two years) that operates globally in attractive and defensible niches of the pharmaceutical industry. The nearer-term earnings appear underpinned by organic opportunities alone, but longer-term growth is dependent on further successful product acquisitions.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »